Your session is about to expire
← Back to Search
Ipilimumab + Chemotherapy for Melanoma
Study Summary
This trial will study the safety of combining the drugs ipilimumab and carboplatin/paclitaxel to treat metastatic melanoma. It will also look at whether the combination can help patients and what features of the immune system may predict who will respond to the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been cancer-free for less than a year, except for certain skin, bladder, or cervical cancers.I have moderate to severe numbness, tingling, or pain in my hands or feet.I am not on treatments like IL 2, interferon, other immune therapies, immunosuppressants, experimental drugs, or long-term steroids.I haven't had vaccines for infectious diseases 1 month before or after ipilimumab.I have been treated with ipilimumab or drugs targeting CTLA-4 before.I am not pregnant, breastfeeding, and can avoid pregnancy during and for 26 weeks after the study.I have advanced melanoma that hasn't been treated with surgery, but I may have had adjuvant therapy or BRAF inhibitors.You have a disease that can be measured or evaluated.I have brain lesions but no symptoms, or they were treated.I do not have autoimmune diseases like Crohn's, lupus, or Guillain-Barre Syndrome.People who are in prison or are being held against their will for treatment cannot participate.I do not have any health or mental conditions that could make treatment risky.I have been diagnosed with malignant melanoma.
- Group 1: B
- Group 2: A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the dangers that have been associated with Ipilimumab?
"While there is some evidence to support the safety of Ipilimumab, it only received a 2 because Phase 2 trials have not yet found efficacy data."
Are patients currently being sought for this clinical trial?
"At the moment, this particular study is not recruiting. However, it was active in the past and was last updated on February 17th, 2021. There are 784 other trials for melanoma and 1534 for Ipilimumab that are currently looking for patients to enroll."
For what purpose is Ipilimumab most often employed?
"Ipilimumab is often used to treat patients with terminal illnesses. It can also be administered to those suffering from cancer in their lymph nodes, fallopian tubes, and testicular germ cells that have become resistant to other treatments."
How many people can join this trial at maximum capacity?
"This particular study has already wrapped up recruitment for new patients. The trial was first posted on November 1st, 2012 and the last update occurred on February 17th, 2021. There are presently 784 other trials actively recruiting patients with melanoma and 1534 studies for Ipilimumab that are looking for participants."
Is Ipilimumab effective for other medical conditions?
"As of now, there are 1534 ongoing studies for Ipilimumab with 373 trials in Phase 3. While most of the studies for Ipilimumab are running out of China, 85559 locations worldwide are operating clinical trials for Ipilimumab."
Share this study with friends
Copy Link
Messenger